Skip to content

In the BioHarmony Drug Report Database


Spinraza (nusinersen) is an oligonucleotide pharmaceutical. Nusinersen was first approved as Spinraza on 2016-12-23. It is used to treat spinal muscular atrophy in the USA. It has been approved in Europe to treat spinal muscular atrophy. Spinraza's patents are valid until 2035-09-11 (FDA).
Trade Name Spinraza
Common Name Nusinersen
Indication spinal muscular atrophy
Drug Class Antisense oligonucleotides
Get full access now